Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Sponsors
CHRISTIAN MEDICAL COLLEGE RANIPET
Eligibility
Inclusion criteria
Inclusion criteria: patients above the age of 30 years with spirometry-confirmed COPD willing to consent for the study and to undergo the process of sputum induction.
Exclusion criteria
Exclusion criteria: Participants will be excluded if they have: 1)Acute respiratory infection or COPD exacerbation within the previous 6 weeks 2)Known bronchial asthma or asthma-COPD overlap syndrome 3)Recent systemic corticosteroid therapy 4)Active pulmonary tuberculosis 5)Significant bronchiectasis or interstitial lung disease 6)Allergic, autoimmune, haematological or parasitic disorders likely to influence eosinophil counts 7)Pregnancy or lactation 8)Haemodynamic instability or inability to safely undergo spirometry or sputum induction procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the prevalence of eosinophilic airway inflammation phenotype in patient presenting with COPDTimepoint: It will be studied after 2 years at the completion of the study with total data | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the correlation between peripheral blood eosinophil count & sputum eosinophil percentage in stable COPD.Timepoint: It will be studied after 2 years at the completion of the study with total data;2. To determine the sensitivity, specificity, positive predictive value, negative predictive value & area under the receiver operating characteristic (ROC) curve of blood eosinophil thresholds for detecting sputum eosinophilia.Timepoint: It will be studied after 2 years at the completion of the study with total data;3. To evaluate associations between eosinophilic airway inflammation & demographic or clinical variables including smoking history, biomass exposure & disease severity.Timepoint: It will be studied after 2 years at the completion of the study with total data;4. To assess the clinical utility of a region-specific blood eosinophil threshold for phenotype-directed COPD management.Timepoint: It will be studied after 2 years at the completion of the study with total data | — |
Countries
India
Contacts
Public ContactDR PRATHYUSHA .KORITALA
CHRISTIAN MEDICAL COLLEGE , RANIPET
Outcome results
None listed